ACADIA Pharmaceuticals Inc. Stock News

Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous syste

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

San Diego, California--(Newsfile Corp. - July 31, 2020) - If you would like to discuss your legal rights email [email protected] or call (619) 780-3993. ACADIA Pharmaceuticals (ACAD) Accused of Misleadi

Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) for breach of fiduciary duties on the part of its directors and management.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact

The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this event..

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Protalix Biotherapeutics

Brokerages expect that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will post earnings per share (EPS) of ($0.45) for the current quarter, according to Zacks Investment Research. Six analysts have made e

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the U.S. financial markets. ACADIA’s

Stocks Analysis by Michael Kramer covering: SPDR S&P 500, Amazon.com Inc, Freeport-McMoran Copper & Gold Inc, US Dollar Index Futures. Read Michael Kramer's latest article on Investing.com

Acadia Pharmaceuticals said Tuesday its experimental depression treatment failed in a Phase 3 study — prompting ACAD stock to plunge. That put shares near their lowest point this month.